Jara Herron, the owner of a salon and day spa in Tulsa, Okla., had just given birth to her seventh child about six years ago when she suddenly felt her chest getting tighter.
When she got to the hospital, Herron learned she was having a heart attack. Her organs soon began to fail, so doctors put her into a medical coma.
Because Herron was not a candidate for a heart transplant, her doctors instead turned to the world’s smallest heart pump, one that can be inserted with a noninvasive catheter. That heart pump saved Herron’s life.
And it’s done the same thing for thousands of other patients around the United States.
But that’s far from the only thing this innovative heart pump has done.
It’s also helped hand investors 569% gains.
Its maker is a cutting-edge medtech firm with deep expertise with heart patients.
Those big gains are just a start for this life sciences leader.
Immunalysis Corp., a unit of diagnostic player Alere Inc. (NYSE: ALR), said last week that its supersensitive new test for detecting the opioid painkiller fentanyl received U.S. Food and Drug Administration (FDA) clearance for use by labs, hospitals, and doctors’ offices.
As we approach Christmas and the end of the year, I’m getting ready for one of my favorite nights.
You see, I love New Year’s Eve.
And not because I look forward to the lavish parties folks like to hold on that final night of the year.
In fact, I don’t party at all.
Instead, my wife and I have established a neat little ritual that lets us say adios to the outgoing year and to welcome in the new one by setting some goals for the one that’s coming in.
We dress up and go out for a late dinner – usually at one of the nice local eateries that we like and support. But before we do, the two of us always sit by the fire and have our most important “family talk” of the year.
Each year, you see, I write an “Annual Report” that details our achievements for that year. These include accomplishments at work and in the civic projects we’re involved with, great investments we’ve made, and projects we’ve completed.
As my wife and I sit by the fire, we review that “report” – and celebrate our accomplishments. And then we establish goals for the New Year – creating an “Investment Action Plan” whose success or failure we’ll review at our “chat” the following New Year’s Eve.
I’m sharing this story for a reason: My wife and I have been doing this for more than a decade now. That’s long enough to see that this “tradition” has had a positive impact on our lives.
And it points to a habit that I believe every investor should develop.
I’m talking about developing an Investment Action Plan.
August 1, 2016, will go down in history as a milestone in stock market history.
For the first time ever, high-tech companies were the four most valuable companies in the Standard & Poor’s 500 Index.
And most investors and analysts didn’t even notice.
That may not sound like a big deal – but it’s actually huge. In fact, it marks the beginning of a whole new era of technology investing.
That’s what I and my research team determined after spending the last 88 days trying to figure out what this anomaly means. We’ve assessed the situation, done hours of research, and have now put together a comprehensive guide laying out what this new world means for you – and your money.
We’ve identified four profit “windows” from which I’ll be finding the “Singularity Plays” with the best chance of producing 10x gains.
This comprehensive report is absolutely free. I’m sending it to you as part of your Strategic Tech Investor membership.
Deep inside your body, skin, joints and muscles deliver messages to your spinal cord, which uses that information to control your movements. Further, your ears, eyes, mouth, nose and skin deliver messages to your brain, which allows you to react, think and plan – and then direct your body to carry out your decisions.
That’s the central nervous system.
And those messages come in the form of electric signals.
For decades, doctors have dreamed of being able to harness those electric signals to treat injuries and disease.
And now, thanks to miniature implantable devices that can alter and control the body’s electric signals, that dream is coming true.
Researchers are calling it “bioelectronic medicine.”
Here’s how it will work.
Take, for example, a child with asthma. With bioelectronics, doctors could wrap tiny devices around nerves in the lungs. Employing those devices, doctors could then alter nervous electric signals in order to ease tension in the lungs.
If everything goes right, no more asthma…
And asthma treatments are just the beginning…
Researchers from the company I want to share with you today are confident bioelectronic medicine can also be used to treat other long-term diseases, including diabetes and arthritis.
And now this company is teaming up with Google parent Alphabet, Inc. (Nasdaq: GOOGL) to forge a brand-new $715 million bioelectronics firm.
Those of you who invested in this company back on March 29, when I first told you about it, have already made more than 11% on your money. That’s nearly double the S&P 500’s return over the same period.
And now this pact with Alphabet puts it in line to continue this strong growth, as it helps you get invested in bioelectronics – a sector that Global Market Insights says is growing at more than 10% a year, 10 times faster than the U.S. economy as a whole.
On Tuesday, I told you we have to start getting “choosier” about the stocks we buy.
And I told you I’d be back soon with our prime choice.
Today I’m keeping that promise.
The roller-coaster market we’ve seen over just the past week – though, really, it’s been with us all year long – brings with it great buying opportunities for tech investors. The earlier rallies that were making some stocks so expensive are largely gone.
One of my main jobs here is to help you make good choices when others are panicking.
So today we’re “putting our best foot forward” by taking a look at a tech leader well off Wall Street’s radar (they think it’s merely a “software” company).
Fitbit Inc. (NYSE: FIT) had a very successful initial public offering (IPO) last week.
Shares of the wearable tech leader soared 48% from their offering price. The success underscores the growth ahead for wearables – especially the health and fitness applications where Fitbit excels.
Forecasters at IDTechEx project sales of wearable electronics will hit $20 billion next year and will be valued at almost $70 billion a decade later.
As much as I like Fitbit and its technology, my concern here is that you could get hurt by chasing this stock. Indeed, the first six months for any IPO is a volatile period in which new issues often give up much of their early gains.
That’s why I think tech investors would do well to take a look at Walt Disney Co. (NYSE: DIS).
You know it as an entertainment powerhouse.
But you need to start looking at the “Mouse House” differently.
Biotechnology is a big opportunity. And China is a big market.
Combine the two and you have a big potential for investment profits.
In today’sStrategic Tech Investor,I’m talking with Money Map PressExecutive Editor William Patalon III, who also heads up the Private Briefing service, about a big profit play in the Chinese biotech market.